Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
1.930
-0.040 (-2.03%)
At close: Jun 27, 2025, 4:00 PM
1.950
+0.020 (1.04%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Nuvation Bio Revenue
Nuvation Bio had revenue of $3.08M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $10.96M. In the year 2024, Nuvation Bio had annual revenue of $7.87M.
Revenue (ttm)
$10.96M
Revenue Growth
n/a
P/S Ratio
48.79
Revenue / Employee
$49,805
Employees
220
Market Cap
656.71M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NUVB News
- 4 days ago - Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers - Business Wire
- 12 days ago - Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - GlobeNewsWire
- 16 days ago - US FDA approves Nuvation Bio's lung cancer therapy - Reuters
- 16 days ago - U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Business Wire
- 5 weeks ago - Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting - Business Wire
- 6 weeks ago - Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 - Business Wire
- 6 weeks ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript - Seeking Alpha